B cell responses to HIV-1 infection and vaccination: Pathways to preventing infection

Trends in Molecular Medicine

Volumn 17, Issue 2, 2011, Pages 108-116

  Haynes, Barton F ^a   Moody, M Anthony ^a   Liao, Hua Xin ^a   Verkoczy, Laurent ^a   Tomaras, Georgia D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALPHA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 15; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHATIDYLSERINE;

ANTIBODY RESPONSE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION; INFECTION PREVENTION; NONHUMAN; REVIEW; VIRUS REPLICATION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; B-LYMPHOCYTES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MUCOUS MEMBRANE; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79651469358     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.10.008     Document Type: Review

References (86)

1. Tomaras G.D., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008, 82:12449-12463.
2. Bar K.J., et al. Molecular targets and potency of HIV-1 neutralization in vivo revealed by dynamic assessment of transmitted/founder virus antibody recognition and escape. AIDS Res. Hum. Retroviruses 2010, 26:A12.
3. Richman D.D., et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4144-4149.
4. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
5. Chun T.W., et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:8869-8873.
6. Yates N.L., et al. HIV Frequently elicits mucosal and plasma Env-specific IgA with a rapid initial decline in acute infection. Journal of AIDS 2009, 51. Abstract No. 142.
7. Levesque M.C., et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009, 6:e1000107.
8. Veazey R.S., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
9. Koup R.A., et al. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol. 1991, 4:215-223.
10. Pollara J., et al. High titers of cross-clade ADCC-mediating antibodies are detectable in plasma samples collected from individuals with broadly neutralizing antibodies. AIDS Res. Hum. Retroviruses 2010, 26:A-21.
11. Stacey A.R., et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 2009, 83:3719-3733.
12. Gasper-Smith N., et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J. Virol. 2008, 82:7700-7710.
13. Moir S., Fauci A.S. B cells in HIV infection and disease. Nat. Rev. Immunol. 2009, 9:235-245.
14. Hazenberg M.D., et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids 2003, 17:1881-1888.
15. Ganesan A., et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J. Infect. Dis. 2010, 201:272-284.
16. Liao H.-X., et al. Early plasma B cell responses to transmitted HIV-1 are directed to envelope gp41 and originate by the activation of mutated B cell clones. AIDS Res. Hum. Retroviruses 2010, 26:A24.
17. Mestecky J., et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses 2004, 20:972-988.
18. Schnittman S.M., et al. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 1986, 233:1084-1086.
19. He B., et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J. Immunol. 2006, 176:3931-3941.
20. Racz P., et al. Follicular dendritic cells in HIV-induced lymphadenopathy and AIDS. APMIS Suppl. 1989, 8:16-23.
21. Tenner-Racz K., et al. Monoclonal antibodies to human immunodeficiency virus: their relation to the patterns of lymph node changes in persistent generalized lymphadenopathy and AIDS. Aids 1987, 1:95-104.
22. Zhang Z.Q., et al. Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology 2007, 361:455-464.
23. Bussmann B.M., et al. Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV. Virology 2010, 397:7-13.
24. Moir S., et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10362-10367.
25. Ehrhardt G.R., et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J. Exp. Med. 2005, 202:783-791.
26. Zandman-Goddard G., Shoenfeld Y. HIV and autoimmunity. Autoimmun. Rev. 2002, 1:329-337.
27. Petrovas C., et al. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J. Autoimmun. 1999, 13:347-355.
28. Moody M.A., et al. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J. Exp. Med. 2010, 207:763-776.
29. Alving C.R. Antibodies to lipids and liposomes: immunology and safety. J. Liposome Res. 2006, 16:157-166.
30. Miranda L.R., et al. The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain. J. Immunol. 2007, 178:7132-7138.
31. Palacios R., Santos J. Human immunodeficiency virus infection and systemic lupus erythematosus. Int. J. STD AIDS 2004, 15:277-278.
32. Haynes B.F., et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 2005, 14:59-67.
33. Stamatatos L., et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 15:866-870.
34. Gray E.S., et al. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J. Virol. 2009, 83:11265-11274.
35. Doria-Rose N.A., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010, 84:1631-1636.
36. Haynes B.F., et al. Is developing an HIV-1 vaccine possible?. Curr. Opin. HIV AIDS 2010, 5:362-367.
37. Corti D., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805.
38. Scheid J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
39. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
40. Wu X., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
41. Bonsignori M., et al. Immunoregulation of HIV-1 broadly neutralizing antibody responses: deciphering maturation paths for antibody induction. AIDS Res. Hum. Retroviruses 2010, 26:A-154.
42. McElrath M.J., Haynes B.F. Induction of long-term immunity to HIV-1 by vaccination. Immunity 2010, 33:542-554.
43. Haynes B.F., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
44. Meffre E., et al. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J. Clin. Invest. 2001, 108:879-886.
45. Shiokawa S., et al. IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J. Immunol. 1999, 162:6060-6070.
46. Wardemann H., et al. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
47. Chen C., et al. The site and stage of anti-DNA B-cell deletion. Nature 1995, 373:252-255.
48. Chen C., et al. Deletion and editing of B cells that express antibodies to DNA. J. Immunol. 1994, 152:1970-1982.
49. Li H., et al. Regulation of anti-phosphatidylserine antibodies. Immunity 2003, 18:185-192.
50. Tiller T., et al. Autoreactivity in human IgG+ memory B cells. Immunity 2007, 26:205-213.
51. Alam S.M., et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20234-20239.
52. Klein J.S., Bjorkman P.J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 2010, 6:e1000908.
53. Mouquet H., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467:591-595.
54. Verkoczy L., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:181-186.
55. Verkoczy L., et al. Role of immunoglobulin light chain usage and MPER specificity in counterselecting B cells expressing the broadly neutralizing antibody 2F5. AIDS Res. Hum. Retroviruses 2010, 26:A-155.
56. Rerks-Ngarm S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
57. Moore P.L., et al. Specificity of the autologous neutralizing antibody response. Curr. Opin. HIV AIDS 2009, 4:358-363.
58. Hessell A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
59. Hladik F., Hope T.J. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 2009, 6:20-28.
60. Florese R.H., et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 2009, 182:3718-3727.
61. DeVico A.L., Gallo R.C. Control of HIV-1 infection by soluble factors of the immune response. Nat. Rev. Microbiol. 2004, 2:401-413.
62. Forthal D.N., et al. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J. Virol. 2005, 79:2042-2049.
63. Forthal D.N., et al. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 2007, 178:6596-6603.
64. Montefiori D.C., Mascola J.R. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?. Curr. Opin. HIV AIDS 2009, 4:347-351.
65. Lambotte O., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. Aids 2009, 23:897-906.
66. Xiao P., et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173.
67. Bonsignori M., et al. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 2009, 183:2708-2717.
68. Morris L., et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 1998, 188:233-245.
69. Gilbert P., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 2010, 202:595-605.
70. Evans T.G., et al. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. Vaccine 2004, 22:2626-2630.
71. Goepfert P.A., et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007, 25:510-518.
72. Amanna I.J., et al. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 2007, 357:1903-1915.
73. Karnasuta C., et al. Magnitude and breadth of the neutralizing antibody response in RV144. AIDS Res. Hum. Retroviruses 2010, 26:A-162.
74. Piantadosi A., et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 2009, 83:10269-10274.
75. van Gils M.J., et al. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J. Virol. 2010, 84:3576-3585.
76. Euler Z., et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 2010, 201:1045-1053.
77. Green N.M., et al. Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J. Immunol. 2009, 183:1569-1576.
78. Shlomchik M.J., et al. Activating systemic autoimmunity: B's, T's, and tolls. Curr. Opin. Immunol. 2009, 21:626-633.
79. Burton D.R., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
80. Zhou T., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
81. Pietzsch J., et al. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J. Exp. Med. 2010, 207:1995-2002.
82. Gorny M.K., et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 2005, 79:5232-5237.
83. Pancera M., et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 2010, 84:8098-8110.
84. Calarese D.A., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
85. Scanlan C.N., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J. Virol. 2002, 76:7306-7321.
86. Astronomo R.D., et al. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J. Virol. 2008, 82:6359-6368.